Drugs / CT-P47
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05188378 | Dec 2021 → Oct 2022 | — | Celltrion | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05725434 | Feb → Apr 2023 | rheumatoid arthritis | Celltrion | Unknown | No outcome recorded |
| Phase 3 | NCT05489224 | Sep 2022 → Jun 2023 | rheumatoid arthritis | Celltrion | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05617183 Comparator | Nov 2022 → Apr 2023 | — | Celltrion | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-P47 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05617183 ↗ |
| Modality | Monoclonal antibody | “CT-P47, containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody” NCT05489224 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT05489224 ↗ |